Thymosin Alpha-1 (10 mg Vial) Dosage Protocol
Thymosin Alpha-1 is a 28-amino-acid peptide originally isolated from thymus extract. It modulates T-cell function and immune response. Approved internationally for hepatitis B and C adjuvant therapy.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Subcutaneous, once daily
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 300 mcg (0.3 mg) | 9 units (0.09 mL) |
| Weeks 2–8 | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
Frequency: Inject once daily subcutaneously. This 8‑week protocol begins at 300 mcg to assess tolerance, then increases to a maintenance dose of 500 mcg daily from Week 2 onward. The 500 mcg daily dose yields ~3.5 mg/week, consistent with clinical dosing ranges. Treatment durations of 8–16 weeks are commonly reported in literature.
For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (Thymosin Alpha-1, 10 mg each) | 8 weeks: approximately 3 vials required (26.6 mg total) 12 weeks: approximately 5 vials required (40.6 mg total) 16 weeks: approximately 6 vials required (54.6 mg total) |
| Insulin Syringes (U‑100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (3 vials): 9 mL — 1 bottle required (10 mL each) 12 weeks (5 vials): 15 mL — 2 bottles required (10 mL each) 16 weeks (6 vials): 18 mL — 2 bottles required (10 mL each) |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs — 2 boxes required (100 swabs each) 12 weeks: 168 swabs — 2 boxes required (100 swabs each) 16 weeks: 224 swabs — 3 boxes required (100 swabs each) |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 7 days, protect from light |
Important Notes
How This Works
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymus tissue. It enhances T-cell maturation, increases CD4+/CD8+ activity, upregulates MHC class I and II antigen presentation, and modulates dendritic cell function via TLR2/TLR9. Effects also include increased type I interferon and IL-12 production.
Potential Benefits & Side Effects
Potential Benefits
- Approved internationally as adjuvant for chronic hepatitis B and C.
- Enhances T-cell maturation and antigen presentation.
- Studied in cancer adjuvant, sepsis, and post-viral immune dysregulation.
- Excellent safety profile — adverse events similar to placebo in trials.
Side Effect Profile
- Generally well-tolerated.
- Mild injection-site reactions.
- Rare: transient muscle atrophy or rash.
Lifestyle Factors
- Adequate sleep, vitamin D, and zinc support immune function.
- Anti-inflammatory diet complements immune-modulatory effects.
Injection Technique
- Subcutaneous, rotate sites.